|
|
|
|
|
|
|
|
|
|
|
|
|
23.04.26 - 07:03
|
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency (Business Wire)
|
|
|
Ad hoc announcement pursuant to Art. 53 LRZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026.
Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy.
Widespread net sales growth of 25.5% year-on-year at constant currency1, aligned with strong growth performance across geographies and product categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%).
Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion.
Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II res...
|
|
|
22.04.26 - 17:48
|
Galderma Shareholders Approve All Annual General Meeting Proposals (Business Wire)
|
|
|
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meeting (AGM), held earlier today via live webcast. This includes the payment of a gross dividend of 0.35 CHF per dividend-bearing share1, to be distributed out of reserves from capital contributions.
Shareholders approved the election of Harry Kirsch as independent member of the Board of Directors, as well as the election of Samuel du Retail and Delphine Viguier-Hovasse, representatives of L'Oréal, as non-independent members of the Board. In addition, Thomas Ebeling (Chair), Daniel Browne, Maria Teresa Hilado, Karen Lee Ling, Roberto Marques, Sherilyn McCoy and Dr. Flemming Ørnskov were re-elected to the Board.
The AGM also approved the company's 2025 Annual Financial Statements, Non-Financial Report and Compensation Report.
Detailed voting results and the official minutes will be publ...
|
|
|
|
|
|
|
22.04.26 - 07:01
|
EQT AB (publ) Q1 Annoucement 2026 (Cision)
|
|
|
Continued strong execution in a volatile market environment
“EQT executed well in a quarter where the market environment was characterized by AI-driven volatility and geopolitical uncertainty. We remained disciplined in selectively pursuing thematic investments, the vast majority of those invested into the AI opportunity. We continued to drive monetizations, highlighted by the $6 billion sale of our remaining public stake in Galderma - the most successful private equity investment ever in terms of capital gain from a single fund. Delivering strong returns at scale is a testament to EQT's...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20.03.26 - 07:00
|
Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting (Business Wire)
|
|
|
The Board of Directors proposes a dividend of 0.35 CHF per registered share
Harry Kirsch proposed as new independent member of the Board of Directors
Delphine Viguier-Hovasse and Samuel du Retail proposed as two non-independent board members from L'Oréal
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published the invitation and agenda for its 2026 Annual General Meeting (AGM), which will be held virtually on April 22, 2026, at 3:00pm CEST.
Dividend proposal
The Board of Directors proposes a dividend of 0.35 CHF per registered share of Galderma following its record 2025 performance. If approved by shareholders, the dividend will be paid out of reserves from capital contributions and, in accordance with applicable tax regulations, will be free from Swiss withholding tax.
Proposed elections to the Board of Directors of Galderma Group AG
As previously announced, and in connection with L'Oréal's increased investment in Galderma, the Boar...
|
|
|
16.03.26 - 14:06
|
Ject′s Board-Certified Physician Assistant Molly Orden Selected as a Galderma Aesthetic Injector Network Trainer (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--JECT, a leading medical aesthetics practice with locations across the country, is proud to announce that board-certified Physician Assistant Molly Orden has been selected as a GAIN (Galderma Aesthetic Injector Network) Trainer. For the past six years, Orden has specialized in aesthetic medicine, and is a staple in JECT's Upper East Side and West Village locations.
Through her position as a trainer, Orden provides other clinicians with advanced education on the Galderma portfolio of injectable treatments, such as Restylane, Sculptra and Dysport. Being a Galderma trainer is a prestigious position - there are only 850 trainers nationwide - and is a distinction that reflects her high level of clinical expertise and leadership. In this role, Orden trains and mentors fellow clinicians, helping them refine their injection techniques, deepen their anatomical understanding, and confidently master these products to deliver safe, natural-looking outcomes.
“I've always been deeply passi...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
